MCID: RTN017
MIFTS: 61

Retinal Detachment

Categories: Eye diseases, Neuronal diseases

Aliases & Classifications for Retinal Detachment

MalaCards integrated aliases for Retinal Detachment:

Name: Retinal Detachment 56 12 29 54 6 42 43 15 17 71
Retinal Detachments 15

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant


HPO:

31
retinal detachment:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:5327
OMIM 56 180050
ICD9CM 34 361.9
MeSH 43 D012163
NCIt 49 C26874
SNOMED-CT 67 42059000
ICD10 32 H33.0 H33.2
MedGen 41 C0035305
SNOMED-CT via HPO 68 263681008
UMLS 71 C0035305

Summaries for Retinal Detachment

MedlinePlus : 42 The retina is a layer of tissue in the back of your eye that senses light and sends images to your brain. It provides the sharp, central vision needed for reading, driving, and seeing fine detail. A retinal detachment lifts or pulls the retina from its normal position. It can occur at any age, but it is more common in people over age 40. It affects men more than women and whites more than African Americans. A retinal detachment is also more likely to occur in people who Are extremely nearsighted Have had a retinal detachment in the other eye Have a family history of retinal detachment Have had cataract surgery Have other eye diseases or disorders Have had an eye injury Symptoms include an increase in the number of floaters, which are little "cobwebs" or specks that float about in your field of vision, and/or light flashes in the eye. It may also seem like there is a "curtain" over your field of vision. A retinal detachment is a medical emergency. If not promptly treated, it can cause permanent vision loss. If you have any symptoms, see an eye care professional immediately. Treatment includes different types of surgery. NIH: National Eye Institute

MalaCards based summary : Retinal Detachment, also known as retinal detachments, is related to persistent hyperplastic primary vitreous, autosomal recessive and vitreoretinopathy, neovascular inflammatory. An important gene associated with Retinal Detachment is COL2A1 (Collagen Type II Alpha 1 Chain), and among its related pathways/superpathways are ERK Signaling and PI3K-Akt signaling pathway. The drugs Diclofenac and Isotretinoin have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are retinal detachment and Decreased viability

OMIM : 56 Primary or spontaneous detachment of the retina occurs due to underlying ocular disease and often involves the vitreous as well as the retina. The precipitating event is formation of a retinal tear or hole, which permits fluid to accumulate under the sensory layers of the retina and creates an intraretinal cleavage that destroys the neurosensory process of visual reception. Vitreoretinal degeneration and tear formation are painless phenomena, and in most cases, significant vitreoretinal pathology is found only after detachment of the retina starts to cause loss of vision or visual field. Without surgical intervention, retinal detachment will almost inevitably lead to total blindness (summary by McNiel and McPherson, 1971). (180050)

Wikipedia : 74 Retinal detachment is a disorder of the eye in which the retina separates from the layer underneath.... more...

Related Diseases for Retinal Detachment

Diseases related to Retinal Detachment via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 658)
# Related Disease Score Top Affiliating Genes
1 persistent hyperplastic primary vitreous, autosomal recessive 34.1 TSPAN12 ATOH7
2 vitreoretinopathy, neovascular inflammatory 33.6 VEGFA GLUL GFAP
3 persistent hyperplastic primary vitreous 33.3 ZNF408 TSPAN12 NDP LRP5 FZD4 ATOH7
4 vitreoretinal degeneration 33.3 COL2A1 COL18A1 COL11A1
5 exudative vitreoretinopathy 33.2 ZNF408 VEGFA TSPAN12 NDP LRP5 FZD4
6 myopia 33.2 VEGFA SERPINF1 RHO COL2A1 COL18A1 COL11A1
7 coats disease 33.1 ZNF408 VEGFA TSPAN12 RS1 RHO NDP
8 microvascular complications of diabetes 5 33.0 VEGFA SERPINF1 RHO PDGFB
9 exudative vitreoretinopathy 2, x-linked 33.0 NDP LRP5 FZD4
10 exudative vitreoretinopathy 1 33.0 ZNF408 VEGFA TSPAN12 SERPINF1 RHO NDP
11 exudative vitreoretinopathy 4 33.0 TSPAN12 NDP LRP5 FZD4
12 microphthalmia 33.0 SERPINF1 NDP LRP5 CTNNB1 ATOH7
13 exudative vitreoretinopathy 3 32.8 TSPAN12 NDP FZD4
14 vitreoretinopathy 32.6 ZNF408 TSPAN12 NDP LRP5 FZD4 CTNNB1
15 macular holes 32.4 VEGFA SERPINF1 RS1
16 retinal perforation 32.2 VEGFA RS1 COL2A1 COL11A1
17 macular retinal edema 31.9 VEGFA SERPINF1 RHO
18 cataract 31.9 VEGFA SERPINF1 RHO CTNNB1 COL2A1 COL18A1
19 strabismus 31.7 RS1 RHO CTNNB1 COL2A1 COL11A1
20 microvascular complications of diabetes 1 31.7 VEGFA SERPINF1 GFAP
21 retinal degeneration 31.5 SERPINF1 RS1 RHO GFAP COL2A1
22 vitreous syneresis 31.2 RS1 COL2A1 COL11A1
23 macular degeneration, age-related, 1 31.2 VEGFA SERPINF1 RS1 RHO GFAP COL18A1
24 chorioretinal scar 31.1 VEGFA RHO
25 retinal vascular disease 31.1 ZNF408 VEGFA TSPAN12 SERPINF1 RHO NDP
26 peripheral retinal degeneration 31.1 ZNF408 TSPAN12 RHO COL2A1
27 eye disease 31.0 VEGFA SERPINF1 RS1 RHO GFAP CTNNB1
28 brittle bone disorder 31.0 SERPINF1 LRP5 CTNNB1 COL2A1
29 retinal telangiectasia 31.0 ZNF408 VEGFA TSPAN12 NDP FZD4
30 osteoporosis-pseudoglioma syndrome 31.0 NDP LRP5 FZD4 CTNNB1
31 leukocoria 30.9 ZNF408 TSPAN12 RS1 NDP LRP5 FZD4
32 norrie disease 30.9 ZNF408 TSPAN12 NDP LRP5 FZD4 CTNNB1
33 vitreoretinal dystrophy 30.9 RS1 COL11A1
34 osteoporosis 30.8 VEGFA NDP LRP5 FZD4 CTNNB1 COL2A1
35 bullous retinoschisis 30.7 VEGFA RS1
36 retinitis pigmentosa 30.7 ZNF408 VEGFA SERPINF1 RS1 RHO GLUL
37 inherited retinal disorder 30.7 RS1 RHO LRP5 FZD4 COL2A1 COL18A1
38 eales disease 30.6 VEGFA SERPINF1
39 preretinal fibrosis 30.6 VEGFA GFAP
40 optic nerve hypoplasia, bilateral 30.6 RHO GLUL GFAP ATOH7
41 brain edema 30.2 VEGFA GLUL GFAP
42 meningioma, familial 30.1 VEGFA PDGFB GFAP CTNNB1
43 fundus dystrophy 30.0 ZNF408 VEGFA TSPAN12 SERPINF1 RS1 RHO
44 lattice degeneration of retina leading to retinal detachment 12.5
45 stickler syndrome, type i, nonsyndromic ocular 12.5
46 diverticulosis of bowel, hernia, and retinal detachment 12.4
47 knobloch syndrome 12.4
48 knobloch syndrome 1 12.1
49 retinoschisis 1, x-linked, juvenile 11.9
50 stickler syndrome 11.8

Comorbidity relations with Retinal Detachment via Phenotypic Disease Network (PDN):


Hypertension, Essential

Graphical network of the top 20 diseases related to Retinal Detachment:



Diseases related to Retinal Detachment

Symptoms & Phenotypes for Retinal Detachment

Human phenotypes related to Retinal Detachment:

31
# Description HPO Frequency HPO Source Accession
1 retinal detachment 31 HP:0000541

Symptoms via clinical synopsis from OMIM:

56
Eyes:
retinal detachment
no myopia

Clinical features from OMIM:

180050

GenomeRNAi Phenotypes related to Retinal Detachment according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-2 9.66 PDGFB
2 Decreased viability GR00221-A-3 9.66 PDGFB
3 Decreased viability GR00240-S-1 9.66 COL11A1 PDGFB
4 Decreased viability GR00249-S 9.66 ATOH7 COL11A1 GLUL NDP VEGFA
5 Decreased viability GR00381-A-1 9.66 GFAP PDGFA SERPINF1
6 Decreased viability GR00386-A-1 9.66 COL11A1 NDP PDGFB
7 Decreased viability GR00402-S-2 9.66 COL18A1 GFAP NDP PDGFA PDGFB RHO

MGI Mouse Phenotypes related to Retinal Detachment:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.35 ATOH7 COL18A1 COL2A1 CTNNB1 FZD4 GFAP
2 nervous system MP:0003631 10.27 ATOH7 COL11A1 COL18A1 COL2A1 CTNNB1 FZD4
3 behavior/neurological MP:0005386 10.24 ADAMTSL4 ATOH7 COL18A1 COL2A1 CTNNB1 FZD4
4 digestive/alimentary MP:0005381 10.03 COL11A1 COL2A1 CTNNB1 FZD4 GFAP PDGFA
5 craniofacial MP:0005382 10 COL11A1 COL18A1 COL2A1 CTNNB1 LRP5 PDGFA
6 normal MP:0002873 9.97 ATOH7 COL2A1 CTNNB1 FZD4 GFAP GLUL
7 pigmentation MP:0001186 9.96 ADAMTSL4 COL18A1 CTNNB1 FZD4 LRP5 NDP
8 hearing/vestibular/ear MP:0005377 9.88 COL11A1 COL2A1 CTNNB1 FZD4 NDP TSPAN12
9 renal/urinary system MP:0005367 9.7 COL18A1 COL2A1 CTNNB1 FZD4 PDGFA PDGFB
10 skeleton MP:0005390 9.61 COL11A1 COL18A1 COL2A1 CTNNB1 LRP5 NDP
11 vision/eye MP:0005391 9.5 ADAMTSL4 ATOH7 COL18A1 COL2A1 CTNNB1 FZD4

Drugs & Therapeutics for Retinal Detachment

Drugs for Retinal Detachment (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 202)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
2
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
3
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
4
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
5
Fosaprepitant Approved Phase 4 172673-20-0 219090
6
Ondansetron Approved Phase 4 99614-02-5 4595
7
Aprepitant Approved, Investigational Phase 4 170729-80-3 6918365 151165
8
Atropine Approved, Vet_approved Phase 4 51-55-8, 5908-99-6 174174
9
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
10
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
11
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
13
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
14
Triazolam Approved, Investigational Phase 4 28911-01-5 5556
15
Dipivefrin Approved Phase 4 52365-63-6 3105
16
Rasagiline Approved Phase 4 136236-51-6 3052776
17
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
18 Sodium Channel Blockers Phase 4
19 Diuretics, Potassium Sparing Phase 4
20 Analgesics Phase 4
21 Analgesics, Non-Narcotic Phase 4
22 Antineoplastic Agents, Immunological Phase 4
23 Anesthetics, Local Phase 4
24 Mitogens Phase 4
25 Endothelial Growth Factors Phase 4
26 Anti-Inflammatory Agents, Non-Steroidal Phase 4
27 Immunoglobulins Phase 4
28 Antibodies Phase 4
29 Ketorolac Tromethamine Phase 4
30 Cyclooxygenase Inhibitors Phase 4
31 Immunoglobulins, Intravenous Phase 4
32 Immunoglobulin G Phase 4
33 Psychotropic Drugs Phase 4
34 Anti-Anxiety Agents Phase 4
35 neurokinin A Phase 4
36
Substance P Phase 4 33507-63-0 44359816
37 Antipsychotic Agents Phase 4
38 Anti-Arrhythmia Agents Phase 4
39 Neurotransmitter Agents Phase 4
40 Respiratory System Agents Phase 4
41 Anti-Asthmatic Agents Phase 4
42 Ophthalmic Solutions Phase 4
43 Parasympatholytics Phase 4
44 Cholinergic Agents Phase 4
45 Muscarinic Antagonists Phase 4
46 Mydriatics Phase 4
47 Cholinergic Antagonists Phase 4
48 Bronchodilator Agents Phase 4
49 Anesthetics Phase 4
50 Immunologic Factors Phase 4

Interventional clinical trials:

(show top 50) (show all 315)
# Name Status NCT ID Phase Drugs
1 Adjunctive Local Application of Lidocaine During Scleral Buckling Under General Anesthesia Unknown status NCT01417572 Phase 4 lidocaine
2 Transpupillary Thermotherapy (TTT) Alone Versus the Combined Therapy Consisting of TTT and Intravitreal Injection of Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Unknown status NCT02379000 Phase 4 Triamcinolone Acetonide
3 Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization Unknown status NCT02033018 Phase 4 Aflibercept Injection
4 Ranibizumabe Intravitreal Injection for Myopic Choroidal Neovascularization Unknown status NCT01246089 Phase 4 ranibizumab injection
5 On-label tReatment With Intravitreal Aflibercept Injection for Patients With Persistent Pigment Epithelial Detachments in Neovascular AMD. Unknown status NCT01670162 Phase 4 Aflibercept
6 Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema. Unknown status NCT03458923 Phase 4 Diclofenac Sodium 0.1 ml containing 500µg;Ranibizumab 0.5 mg Solution for Injection
7 Topical Application of ACULAR a Randomized, Vehicle Controlled Clinical Trial: Efficiency in Inhibiting Proliferative Retinopathy of Prematurity Unknown status NCT00634972 Phase 4 ACULAR;REFRESH TEARS;placebo
8 Different Day Regimes of Preoperative CONbercept Administration on CytokinEs of Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: a Prospective Randomized Controlled Clinical Trial (CONCEPT) Unknown status NCT03506750 Phase 4 IVC
9 Comparison of the Ahmed Glaucoma Valve FP7 and FP8 in Pediatric Glaucoma: a Randomized Clinical Trial. Unknown status NCT01494974 Phase 4
10 New Horizons in the Treatment of Vitreous Floaters: Efficacy and Safety of Vitreolysis With the Ultra Q Reflex YAG Laser (Ellex) Unknown status NCT02812004 Phase 4
11 Determining the Effect of Low-dose Isotretinoin on Proliferative Vitreoretinopathy Completed NCT01445028 Phase 4 Isotretinoin
12 Bevacizumab Intravitreal for Myopic Choroidal Neovascularization Completed NCT00797992 Phase 4 Injection
13 Intravitreal Ranibizumab in Patients With Retinal Pigment Epithelial Detachments Secondary to Age-related Macular Degeneration Completed NCT00976222 Phase 4 intravitreal injection with ranibizumab
14 Open Label Study: Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment. Completed NCT01722656 Phase 4 Aflibercept
15 The Effects of Triamcinolone Acetonide With Retrobulbar Anesthesia on Postoperative Pain Control Following Vitreoretinal Surgery Completed NCT01995045 Phase 4 Triamcinolone;Bupivicaine Hydrochloride
16 Evaluating the Safety and Efficacy of Polyglycolic Acid Suture in Ophthalmic Surgical Procedures Completed NCT00351429 Phase 4
17 Preoperative Ketorolac for Intraoperative and Postoperative Pain Management in Scleral Buckling Surgery Under Retrobulbar Block Anesthesia: A Prospective, Randomized, Controlled Study Completed NCT02729285 Phase 4 Ketorolac Tromethamine;placebo
18 A 12-month, Exploratory Open-label Study of Eylea (Aflibercept) in Subjects With Retinal Pigment Epithelial Detachment Secondary to Neovascular Age-related Macular Degeneration Completed NCT02142296 Phase 4 Eylea
19 Different Conbercept Injection Methods in Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT02816710 Phase 4 Conbercept
20 Comparison of Dexmedetomidine vs. Propofol in Vitreoretinal Surgery Under Sub-Tenon's Block Completed NCT01001429 Phase 4 Dexmedetomidine infusion;propofol
21 Evaluation on Efficacy of Topical Nepafenac as Supplement Therapy in the Treatment of Diabetic Macular Edema Completed NCT02443012 Phase 4 Topical Gutt Nepafenac 0.1%
22 Prospective Randomized Controlled Study of Intravitreal Injection of 0.16 mg Bevacizumab One Day Before Surgery for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4 Bevacizumab
23 Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous and Subretinal Fluid in Patients With Retinopathy of Prematurity Stage IV and V Completed NCT00563121 Phase 4
24 Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous and Subretinal Fluid in Patients With Retinopathy of Prematurity Stage V. Completed NCT00500396 Phase 4
25 Evaluation of the Effect of Repeated Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using Optical Coherence Tomography Angiography Completed NCT03246152 Phase 4 Bevacizumab
26 A Comparison of Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients Completed NCT00738621 Phase 4 Aprepitant, Dexamethasone, Ondansetron;Aprepitant, Dexamethasone, Placebo
27 A Study to Investigate the Safety and Efficacy of Lucentis (Ranibizumab) in Patients With CNV Due to Causes Other Than AMD and in Patients Where Pigment Epithelial Detachments Are the Primary Manifestation of Their AMD. Completed NCT01628354 Phase 4 Ranibizumab
28 Prospective, Single-center, Six-month Study of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy: Effects on Microaneurysm Turnover and Non-perfused Retinal Area Completed NCT02834663 Phase 4 Lucentis
29 Intravitreal Aflibercept (VEGF Trap-Eye) in Neovascular Age-related Macular Degeneration With Limited Response to Ranibizumab Completed NCT02309281 Phase 4 aflibercept 2mg
30 Atropine for Children and Adolescent Myopia Progression Study (ACAMP) Enrolling by invitation NCT03949101 Phase 4 Atropine Sulfate 1 % Ophthalmic Ointment and Atropine Sulfate 0.01% Eye Drop;atropine 0.01% eye drop
31 Comparative Analysis of Oral Sedation Versus Standard Intravenous Sedation in Vitreoretinal Surgery With Topical Anesthesia and Sub-tenon's Block Not yet recruiting NCT04346095 Phase 4 Oral Sedatives with or Without Analgesia;Intravenous Sedatives with or Without Analgesia
32 Subtenons Triamcinolone Acetonide Injections for Treatment of Persistent Choroidal Effusions Post Glaucoma Surgery Not yet recruiting NCT02917564 Phase 4 Triamcinolone Acetonide 1 ml of 40 mg/mL suspension
33 Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment Terminated NCT02068625 Phase 4 Rasagiline;Placebo
34 Effect of Dexamethasone on Postoperative Symptoms of Scleral Buckling Surgery Patients: a Randomized Control Trial Withdrawn NCT01326585 Phase 4 Dexamethasone Sodium Phosphate Injection;Saline Injection
35 Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy. Withdrawn NCT01666236 Phase 4
36 This is an Open Label Study to Evaluate the Efficacy of Intravitreal Aflibercept Injection 2mg in Patients With a Persistent FVPED Despite at Least 6 Consecutive Injections With Ranibizumab 0.5 mg Withdrawn NCT01495208 Phase 4 Aflibercept
37 Comparison of Two High-Density Silicone Oils in Complicated Rhegmatogenous Retinal Detachment Unknown status NCT00403702 Phase 2, Phase 3 Oxane HD [oil-RMN3-mixture];Densiron [(F6H8)
38 Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment Unknown status NCT00370201 Phase 3 colchicine
39 Surgical Management of Pseudophakic and Aphakic Retinal Detachment; a Randomized Clinical Trial Unknown status NCT00370279 Phase 3
40 Pressurized Perfluorocarbon Perfused 23 GA Vitrectomy in Complicated Diabetic Retinal Detachment Unknown status NCT00404209 Phase 3
41 Perfluorocarbon Perfused Vitrectomy and 3D Vitrectomy System in Advanced Diabetic Retinopathy Unknown status NCT00407108 Phase 3
42 Intravitreal Bevacizumab for Management of Active Progressive Proliferative Diabetic Retinopathy (PDR) Unknown status NCT00370721 Phase 3 bevacizumab
43 25-Gauge Vitrectomy Combine With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in Chinese Patients Unknown status NCT02328118 Phase 2, Phase 3 Ranibizumab;Triamcinolone Acetonide
44 The Early Treatment for Retinopathy of Prematurity Study (ETROP) Unknown status NCT00027222 Phase 2, Phase 3
45 A Trial of Bifocals in Myopic Children With Esophoria Unknown status NCT00000128 Phase 3
46 An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy Completed NCT00996437 Phase 2, Phase 3 Ranibizumab;Saline
47 Randomized Clinical Trial of Cryotherapy Versus Postoperative Laser Photocoagulation for Retinopexy in Scleral Buckle Surgery Completed NCT01068379 Phase 3
48 Comparison of Air and Expansile Gas in Pneumatic Retinopexy Completed NCT00120445 Phase 3
49 Triamcinolone Acetonide in Silicone-Filled Eyes as Adjunctive Treatment for Proliferative Vitreoretinopathy Completed NCT00373282 Phase 3 Triamcinolone acetonide
50 Interest of Intravitreal Corticotherapy as the First-line Treatment for Post-operative Endophthalmitis. Completed NCT01768078 Phase 3

Search NIH Clinical Center for Retinal Detachment

Cochrane evidence based reviews: retinal detachment

Genetic Tests for Retinal Detachment

Genetic tests related to Retinal Detachment:

# Genetic test Affiliating Genes
1 Retinal Detachment 29

Anatomical Context for Retinal Detachment

MalaCards organs/tissues related to Retinal Detachment:

40
Eye, Retina, Endothelial, Testes, Bone, Brain, Breast

Publications for Retinal Detachment

Articles related to Retinal Detachment:

(show top 50) (show all 18558)
# Title Authors PMID Year
1
Improving outcomes in retinal detachment: the potential role of rho-kinase inhibitors. 61 42
32235252 2020
2
Surgical treatment for type II macular hole retinal detachment in pathologic myopia. 61 42
32332602 2020
3
Characteristics of diabetic macular edema patients with serous retinal detachment. 61 42
31860985 2019
4
Vitreous levels of VEGF, IL-8, and TNF-alpha in retinal detachment. 54 61
20465445 2010
5
Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor. 61 54
19643496 2009
6
The effects of transient retinal detachment on cavity size and glial and neural remodeling in a mouse model of X-linked retinoschisis. 61 54
19387072 2009
7
Resolution of persistent exudative retinal detachment in a case of Sturge-Weber syndrome with anti-VEGF administration. 61 54
19657986 2009
8
Upregulation of Semaphorin 3A and the associated biochemical and cellular events in a rat model of retinal detachment. 61 54
18815803 2009
9
Treatment of total exudative retinal detachment due to central retinal vein occlusion by intravitreal bevacizumab in a patient with p-ANCA vasculitis. 54 61
19668494 2007
10
Intraretinal immunohistochemistry findings in proliferative vitreoretinopathy with retinal shortening. 54 61
16679807 2006
11
Detection of PEDF in subretinal fluid of retinal detachment: possible role in the prevention of subretinal neovascularization. preliminary results. 54 61
16679806 2006
12
Association of genetic polymorphisms of vascular endothelial growth factor and risk for proliferative retinopathy of prematurity. 61 54
15635051 2005
13
High TGF-beta2 levels during primary retinal detachment may protect against proliferative vitreoretinopathy. 61 54
15505063 2004
14
A case of Kniest dysplasia with retinal detachment and the mutation analysis. 61 54
14644246 2003
15
Frizzled 4 gene (FZD4) mutations in patients with familial exudative vitreoretinopathy with variable expressivity. 54 61
14507768 2003
16
Diabetic patients and retinal proliferation: an evaluation of the role of vascular endothelial growth factor (VEGF). 54 61
12845559 2003
17
Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment. 54 61
12670875 2003
18
Up-regulation of glial fibrillary acidic protein in response to retinal injury: its potential role in glial remodeling and a comparison to vimentin expression. 61 54
14692684 2003
19
Basic fibroblast growth factor, glutamine synthetase, and interleukin-6 in vitreous fluid from eyes with retinal detachment complicated by proliferative vitreoretinopathy. 54 61
12208248 2002
20
Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. 54 61
11914216 2002
21
Levels of basic fibroblast growth factor, glutamine synthetase, and interleukin-6 in subretinal fluid from patients with retinal detachment. 61 54
11589877 2001
22
Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy. 54 61
11264138 2001
23
Concentration of vascular endothelial growth factor in the subretinal fluid of retinal detachment. 54 61
11110038 2000
24
Photoreceptor-specific expression of platelet-derived growth factor-B results in traction retinal detachment. 54 61
10980138 2000
25
Clinical factors related to the aqueous levels of vascular endothelial growth factor and hepatocyte growth factor in proliferative diabetic retinopathy. 61 54
11148602 2000
26
Fibrinolytic activity of subretinal fluid after cryopexy. 61 54
10651193 1999
27
Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. 61 54
10067974 1999
28
Elevated vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. 54 61
12579655 1999
29
Ocular complications and a new surgical approach to lens dislocation in homocystinuria due to cystathionine-beta-synthetase deficiency. 61 54
9587034 1998
30
Vascular endothelial growth factor upregulation in human central retinal vein occlusion. 54 61
9499769 1998
31
[Concentration of vascular endothelial growth factor within the subretinal space and vitreous fluid in rhegmatogenous retinal detachment]. 54 61
9209137 1997
32
[Biological activity of subretinal fluid in selected in vitro tests]. 61 54
9685781 1997
33
Blood-ocular barrier breakdown in eyes with ocular melanoma. A potential role for vascular endothelial growth factor/vascular permeability factor. 54 61
7485392 1995
34
Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. 61 54
7540233 1995
35
Glial fibrillary acidic protein and its mRNA: ultrastructural detection and determination of changes after CNS injury. 54 61
1486005 1992
36
Cytokines in proliferative vitreoretinopathy. 61 54
1800167 1991
37
Minimally interface vitrectomy for rhegmatogenous retinal detachment with a single break in young patients. 61
32551398 2020
38
Adams Oliver syndrome: A mimicker of familial exudative vitreoretinopathy. 61
32420513 2020
39
RECURRENCES OF RETINAL DETACHMENT AFTER RETINECTOMY: Causes and Outcomes. 61
31365519 2020
40
Hyperreflective foci in diabetic macular edema with serous retinal detachment: association with dyslipidemia. 61
32114640 2020
41
INTERNAL LIMITING MEMBRANE PEELING VERSUS NONPEELING TO PREVENT EPIRETINAL MEMBRANE DEVELOPMENT IN PRIMARY RHEGMATOGENOUS RETINAL DETACHMENT: A Swept-Source Optical Coherence Tomography Study With a New Postoperative Classification System. 61
31313717 2020
42
A novel variant in DOCK6 gene associated with Adams-Oliver syndrome type 2. 61
32498638 2020
43
Ocular complications and prophylactic strategies in Stickler syndrome: a systematic literature review. 61
32316871 2020
44
Bilateral serous retinal detachments associated with burkitt lymphoma. 61
32195444 2020
45
AUTOLOGOUS NEUROSENSORY RETINAL TRANSPLANT TO TREAT REFRACTORY SEROUS RETINAL DETACHMENT SECONDARY TO OPTIC DISC COLOBOMA. 61
32568957 2020
46
Study protocol for prognosis and treatment strategy of peripheral persistent avascular retina after intravitreal anti-VEGF therapy in retinopathy of prematurity. 61
32513245 2020
47
Late-Onset Retinal Findings and Complications in Untreated Retinopathy of Prematurity. 61
32059986 2020
48
Baerveldt implant versus trabeculectomy as the first filtering surgery for uncontrolled primary congenital glaucoma: a randomized clinical trial. 61
32490976 2020
49
Inherited and de novo biallelic pathogenic variants in COL11A1 result in type 2 Stickler syndrome with severe hearing loss. 61
32578940 2020
50
Coccidioidal Endophthalmitis: Excellent Recovery of Vision with Aggressive Use of Intravitreal Antifungals and Vitrectomy. 61
32541432 2020

Variations for Retinal Detachment

ClinVar genetic disease variations for Retinal Detachment:

6 ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 RHO NM_000539.3(RHO):c.891C>G (p.Ser297Arg)SNV Pathogenic 523376 rs142285818 3:129251570-129251570 3:129532727-129532727
2 COL2A1 NM_001844.5(COL2A1):c.842_843insT (p.Gly282fs)insertion Pathogenic 812293 12:48387804-48387805 12:47994021-47994022
3 NDP NM_000266.4(NDP):c.308_311dup (p.Lys104fs)duplication Likely pathogenic 523342 rs1555976049 X:43809135-43809136 X:43949889-43949890
4 EYS NM_001142800.2(EYS):c.4152del (p.Pro1385fs)deletion Uncertain significance 523414 rs1185686653 6:65301608-65301608 6:64591715-64591715

Expression for Retinal Detachment

Search GEO for disease gene expression data for Retinal Detachment.

Pathways for Retinal Detachment

Pathways related to Retinal Detachment according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.63 VEGFA PDGFB PDGFA LRP5 FZD4 CTNNB1
2
Show member pathways
12.79 VEGFA PDGFB PDGFA FZD4 CTNNB1 COL2A1
3
Show member pathways
12.55 PDGFB PDGFA COL2A1 COL18A1 COL11A1
4 12.46 VEGFA PDGFB PDGFA LRP5 FZD4 CTNNB1
5
Show member pathways
12.28 PDGFB PDGFA FZD4 CTNNB1
6
Show member pathways
12.26 SERPINF1 LRP5 FZD4 CTNNB1
7 11.98 VEGFA LRP5 FZD4 CTNNB1
8
Show member pathways
11.94 VEGFA RHO PDGFB PDGFA CTNNB1 COL2A1
9 11.81 VEGFA PDGFB PDGFA CTNNB1
10 11.73 GFAP CTNNB1 COL2A1
11 11.5 PDGFB PDGFA FZD4 CTNNB1
12 11.29 VEGFA PDGFB PDGFA
13 11.21 VEGFA PDGFB PDGFA
14 11.15 VEGFA PDGFB PDGFA GFAP
15 10.7 PDGFB PDGFA GFAP COL2A1 COL18A1 COL11A1

GO Terms for Retinal Detachment

Cellular components related to Retinal Detachment according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.02 VEGFA SERPINF1 RS1 PDGFB PDGFA NDP
2 extracellular space GO:0005615 9.96 VEGFA SERPINF1 RS1 PDGFB PDGFA NDP
3 basement membrane GO:0005604 9.65 SERPINF1 COL2A1 COL18A1
4 endoplasmic reticulum lumen GO:0005788 9.63 PDGFB PDGFA COL2A1 COL18A1 COL11A1 ADAMTSL4
5 collagen trimer GO:0005581 9.61 COL2A1 COL18A1 COL11A1
6 platelet alpha granule lumen GO:0031093 9.54 VEGFA PDGFB PDGFA
7 glial cell projection GO:0097386 9.46 GLUL GFAP
8 extracellular matrix GO:0031012 9.43 VEGFA NDP COL2A1 COL18A1 COL11A1 ADAMTSL4
9 Wnt signalosome GO:1990909 9.4 LRP5 CTNNB1
10 collagen-containing extracellular matrix GO:0062023 9.17 SERPINF1 PDGFB NDP COL2A1 COL18A1 COL11A1

Biological processes related to Retinal Detachment according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 multicellular organism development GO:0007275 10.08 VEGFA RS1 PDGFB PDGFA LRP5 LDB2
2 nervous system development GO:0007399 10.02 VEGFA NDP LDB2 CTNNB1 ATOH7
3 positive regulation of cell proliferation GO:0008284 10 VEGFA PDGFB PDGFA LRP5 CTNNB1 COL18A1
4 negative regulation of gene expression GO:0010629 9.92 VEGFA SERPINF1 PDGFB CTNNB1
5 positive regulation of cell migration GO:0030335 9.91 VEGFA PDGFB PDGFA COL18A1
6 angiogenesis GO:0001525 9.85 VEGFA TSPAN12 PDGFA GLUL COL18A1
7 positive regulation of DNA-binding transcription factor activity GO:0051091 9.8 NDP LRP5 FZD4 CTNNB1
8 response to wounding GO:0009611 9.78 PDGFB PDGFA GFAP
9 canonical Wnt signaling pathway GO:0060070 9.77 LRP5 FZD4 CTNNB1
10 Wnt signaling pathway GO:0016055 9.77 TSPAN12 NDP LRP5 FZD4 CTNNB1
11 vasculogenesis GO:0001570 9.75 VEGFA FZD4 CTNNB1
12 positive regulation of MAP kinase activity GO:0043406 9.74 VEGFA PDGFB PDGFA
13 visual perception GO:0007601 9.73 RS1 RHO NDP COL2A1 COL18A1 COL11A1
14 heart morphogenesis GO:0003007 9.72 VEGFA COL2A1 COL11A1
15 positive regulation of cell division GO:0051781 9.71 VEGFA PDGFB PDGFA
16 negative regulation of platelet activation GO:0010544 9.59 PDGFB PDGFA
17 proteoglycan metabolic process GO:0006029 9.58 COL2A1 COL11A1
18 positive regulation of protein autophosphorylation GO:0031954 9.58 VEGFA PDGFB PDGFA
19 retinal blood vessel morphogenesis GO:0061304 9.56 LRP5 FZD4
20 positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway GO:0035793 9.51 PDGFB PDGFA
21 retina vasculature morphogenesis in camera-type eye GO:0061299 9.5 NDP LRP5 FZD4
22 negative regulation of phosphatidylinositol biosynthetic process GO:0010512 9.43 PDGFB PDGFA
23 extracellular matrix-cell signaling GO:0035426 9.33 NDP LRP5 FZD4
24 positive regulation of mesenchymal cell proliferation GO:0002053 9.26 VEGFA PDGFA LRP5 CTNNB1
25 extracellular matrix organization GO:0030198 9.17 PDGFB PDGFA GFAP COL2A1 COL18A1 COL11A1

Molecular functions related to Retinal Detachment according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix structural constituent conferring tensile strength GO:0030020 9.43 COL2A1 COL18A1 COL11A1
2 Wnt-activated receptor activity GO:0042813 9.33 TSPAN12 LRP5 FZD4
3 growth factor receptor binding GO:0070851 9.32 PDGFB PDGFA
4 platelet-derived growth factor receptor binding GO:0005161 9.13 VEGFA PDGFB PDGFA
5 platelet-derived growth factor binding GO:0048407 8.8 PDGFB PDGFA COL2A1

Sources for Retinal Detachment

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....